CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA